These kind of posts show why retail investors are clueless (as are many dev biotech management teams) about FINANCE.
As every other dev small cap biotech, Calithera has to focus on the area of least resistance right now. They don't have the financial luxury to investigate every hunch, nor stop/change focus in mid-stream to chase a hypothesis because you or I want them to. Developing a biotech takes a lot of time and A LOT OF MONEY!
Cala's #1 priority right now is to see thru the Cantata trial. get correct data, and register for AA, then an NDA > commercial drug on market by 2021 will give company the leverage they need to engage in other hypothesis, such as the one you mention here.
Equal with this is for Cala to close a partnership deal for CB-708.
Their focus is not, nor should be what you are saying now because they simply don't have the resources or financial means. In order for them to chase what you suggest now, they'd have to raise once more which would not be supported, and you would be whining once again because you simply do not understand how the dynamics of a correctly run dev. biotech works.
I've read your other whining posts on how their raise last year hurts their biz moving forward and other various ranting - their raise hurts your equity and your patience.
However, you certainly sound like a trader to me which is fine, but please leave the developing a biotech to Susan and CO, who have done a good job up to this point. Now, you are always free to sell out your position and even short it.